America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How do the results from testing AOH1996 on cancer cell lines inform its potential effectiveness in human clinical trials?
**Interview with Dr. Linda Malkas on Breakthrough Cancer Drug Development**
**Editor**: Welcome, Dr. Linda Malkas, and thank you for joining us today to discuss this exciting development in cancer treatment.
**Dr. Malkas**: Thank you for having me! I’m excited to share our research with your audience.
**Editor**: You and your team at the City of Hope Hospital have developed a new targeted chemotherapy drug called AOH1996. Can you explain how this drug works and what makes it unique?
**Dr. Malkas**: Certainly! AOH1996 is designed to specifically target a variant of the PCNA protein, which plays a crucial role in DNA replication and tumor growth. We envision PCNA as a large airline terminal; in cancer cells, it has unique mutations that allow us to effectively ‘shut down’ just the pathways that the cancer cells use, much like canceling only specific flights in an airport without affecting normal operations.
**Editor**: That’s a fascinating analogy! In your research, you tested this drug on over 70 cancer cell lines. What were some of the key findings?
**Dr. Malkas**: We found that AOH1996 selectively killed cancer cells while sparing healthy cells. It disrupts the normal reproductive cycle of these cancer cells, which is critical for their survival. The results were promising, showing effectiveness across various types of cancer, including breast, prostate, and lung cancers.
**Editor**: Looking ahead, what are the next steps for AOH1996?
**Dr. Malkas**: The next phase involves advancing our research into clinical trials in humans. We’re optimistic about the potential for AOH1996 to offer a new line of defense against several hard-to-treat cancers.
**Editor**: That’s encouraging news. How do you think this targeted approach can change the landscape of cancer treatment?
**Dr. Malkas**: Targeted treatments like AOH1996 represent a shift towards more personalized cancer therapy. By focusing on the specific mutations present in cancer cells, we can reduce side effects and improve outcomes. This approach not only enhances efficacy but also paves the way for future innovations in cancer care.
**Editor**: Thank you, Dr. Malkas, for sharing these insights and for your groundbreaking work in the fight against cancer. We look forward to hearing more as your research progresses.
**Dr. Malkas**: Thank you! I appreciate the opportunity to discuss our work, and I’m hopeful about what lies ahead for cancer research.
